CRMD CorMedix Inc.

8.29
-0.16  -2%
Previous Close 8.45
Open 8.44
Price To Book 39.48
Market Cap 197302000
Shares 23,800,000
Volume 422,851
Short Ratio 5.72
Av. Daily Volume 637,251

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim analysis July 25, 2018 by DSMB recommended trial to be stopped early as sufficient efficacy has been demonstrated. Top-line data released January 2019.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program
  2. CorMedix Notified of Compliance with NYSE American Listing Requirements
  3. Is CorMedix, Inc. (NYSEMKT:CRMD) Overpaying Its CEO?
  4. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  5. CorMedix Confirms Previously Announced One-For-Five Reverse Stock Split
  6. CorMedix Inc. Announces Appointment of Phoebe Mounts as Executive Vice President and General Counsel
  7. CorMedix Inc. Reports Fourth Quarter And Full-Year 2018 Financial Results, Announces Reverse Stock Split And Provides Business Update
  8. CorMedix Inc. to Present at Roth and Oppenheimer & Co. Investor Conferences
  9. Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
  10. CorMedix Inc. to Report Year Ended December 31, 2018 Financial Results on Thursday, March 14
  11. CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors
  12. Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  13. Biotech Bounce Just Getting Started
  14. Here's Why CorMedix Dropped as Much as 27.1% Today
  15. CorMedix Inc. Announces FDA Meeting Update
  16. Biotech and Cannabis Stocks That Are Emerging
  17. These Healthcare Stocks Could Surpass Investor Expectations
  18. Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results
  19. Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth
  20. Options Traders Expect Huge Moves in CorMedix (CRMD) Stock